AdaptVac ApS
Press Release, 2020-January-07

Granting of AdaptVac's core platform technology patent in the United States

Hørsholm, Denmark, January 07, 2020 – AdaptVac announces granting of its U.S. patent "Virus-like particle with efficient epitope display" by the USPTO. The patent provides intellectual property protection for the U.S. market of AdaptVac's novel viral capsid-like particle (CLP) technology platform, and any vaccine produced using it (e.g. our Her2 immunotherapy, AV001). Furthermore, granting of the patent in the U.S. validates the patentability of AdaptVac's technology platform patent portfolio, and represents a significant value inflection point for the company.

"*Granting of our CLP platform technology patent in the world's largest market represents enormous value to AdaptVac. We are therefore delighted by this decision and the support it affords our full pipeline of breakthrough vaccines and immunotherapies*", says Dr. Wian de Jongh, AdaptVac's CEO.

Strong patent protection for AdaptVac's pipeline
The granting of our core patent in the U.S. expands AdaptVac's patent protection to include our entire pipeline of vaccines and immunotherapies in develop. This includes our novel heart disease therapy, targeting cholesterol reduction, as well as a long list of viral, bacterial, and additional chronic disease vaccines. This patent also further strengthens the patent protection of our Her2+ cancer immunotherapy, AV001, for which we previously had a divisional patent granted in the U.S.

Value creation through collaborative efforts and external validation by independent research groups
The strength of this patent ensures that we can freely collaborate with some of the best academic research groups to develop truly breakthrough solutions to some of the world's most challenging unmet medical needs. A recent example of an independent research group validating our CLP technology come through a 2019 Nature publication by Amelia Escalano *et al.* (https://www.nature.com/articles/s41586-019-1250-z), at The Rockefeller University, NY, USA. This publication shows their HIV-CLP vaccine induced precursors of broadly neutralizing antibodies, the holy-grail of HIV vaccine research, in non-human primates.

"*We are particularly pleased by the USPTO's acknowledgement of the novel and breakthrough nature of our technology platform, and our ability to deliver improved vaccines and immunotherapies derived from the near infinite variety of viral capsids present in nature.*", says Associate Prof. Adam Sander, AdaptVac's CSO.

Strong worldwide market potential in breast cancer
Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is tailored to be highly competitive both in terms of cost and efficacy, thus aiming at a significant market share.

About AdaptVac ApS
AdaptVac is a joint venture between ExpreS^{2}ion Biotechnologies and NextGen Vaccines, combining ExpreS^{2}ion's platform with novel proprietary and ground-breaking virus-like particle (VLP) technology developed at the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders**.**

AdaptVac ApS
Press Release, 2020-January-07

For further information about AdaptVac ApS, please contact:
Dr. Wian de Jongh, CEO
Telephone: +45 26394649
E-mail: wdj@adaptvac.com

This press release was submitted for publication through the agency of the contact person set out above on January 07, 2020.